{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:49:20Z","timestamp":1791485360734,"version":"4.3.4"},"reference-count":106,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T00:00:00Z","timestamp":1558569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to insufficient growth and late pubertal development in cases of disease onset during childhood or adolescence. During the last decade, the role of anti-tumor necrosis factor (TNF) in the treatment of paediatric-onset IBD has gained more ground. The number of biologicals presently available for children and adolescents with IBD has increased, biosimilars have become available, and practices in adult gastroenterology with regards to anti-TNF have changed. The aim of this study is to review the current evidence on the indications, judicious use, effectiveness and safety of anti-TNF agents in paediatric IBD. A PubMed literature search was performed and included articles published after 2000 using the following terms: child or paediatric, Crohn, ulcerative colitis, inflammatory bowel disease, anti-TNF, TNF alpha inhibitor, infliximab, adalimumab, golimumab and biological. Anti-TNF agents, specifically infliximab and adalimumab, have proven to be effective in moderate and severe paediatric IBD. Therapeutic drug monitoring increases therapy effectiveness and safety. Clinical predictors for anti-TNF response are currently of limited value because of the variation in outcome definitions and follow-ups. Future research should comprise large cohorts and clinical trials comparing groups according to their risk profile in order to provide personalized therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms20102529","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T02:22:00Z","timestamp":1558664520000},"page":"2529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":104,"title":["A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"20","author":[{"given":"Martine A.","family":"Aardoom","sequence":"first","affiliation":[{"name":"Department of Paediatric Gastroenterology, The Erasmus MC Sophia Children\u2019s Hospital, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gigi","family":"Veereman","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology and Nutrition, Kidz Health Castle UZ Brussels, Free University Brussels, B-1090 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Paediatric Gastroenterology, The Erasmus MC Sophia Children\u2019s Hospital, 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/ajg.2017.228","article-title":"Dramatic increase in incidence of ulcerative colitis and crohn\u2019s disease (1988-2011): A population-based study of french adolescents","volume":"113","author":"Ghione","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ajg.2017.97","article-title":"Trends in epidemiology of pediatric inflammatory bowel disease in canada: Distributed network analysis of multiple population-based provincial health administrative databases","volume":"112","author":"Benchimol","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3748\/wjg.v23.i6.1067","article-title":"Disease impact on the quality of life of children with inflammatory bowel disease","volume":"23","author":"Chouliaras","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/apt.12930","article-title":"Long-term safety and efficacy of certolizumab pegol in the treatment of crohn\u2019s disease: 7-year results from the precise 3 study","volume":"40","author":"Sandborn","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for crohn\u2032s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1756284818821266","DOI":"10.1177\/1756284818821266","article-title":"Golimumab in the treatment of ulcerative colitis","volume":"12","author":"Cunningham","year":"2019","journal-title":"Therap Adv. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ecco\/espghan on the medical management of pediatric crohn\u2019s disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/apt.15094","article-title":"Increased prevalence of anti-tnf therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood","volume":"49","author":"Ashton","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cgh.2013.01.012","article-title":"Adalimumab and infliximab are equally effective for crohn\u2019s disease in patients not previously treated with anti-tumor necrosis factor-alpha agents","volume":"11","author":"Kestens","year":"2013","journal-title":"Clin Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ecco-jcc\/jjy156","article-title":"A propensity score-matched comparison of infliximab and adalimumab in tumour necrosis factor-alpha inhibitor-naive and non-naive patients with crohn\u2019s disease: Real-life data from the sicilian network for inflammatory bowel disease","volume":"13","author":"Macaluso","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/apt.13671","article-title":"The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-tnf-alpha naive crohn\u2032s disease","volume":"44","author":"Narula","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/apt.13808","article-title":"Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of crohn\u2019s disease","volume":"44","author":"Cosnes","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ecco-jcc\/jjy087","article-title":"Efficacy of adalimumab for treatment of perianal fistula in children with moderately to severely active crohn\u2019s disease: Results from imagine 1 and imagine 2","volume":"12","author":"Ruemmele","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MPG.0b013e3181a70f21","article-title":"Infliximab therapy in children with concurrent perianal crohn disease: Observations from reach","volume":"49","author":"Crandall","year":"2009","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: Ambulatory care- an evidence-based guideline from ecco and espghan","volume":"67","author":"Turner","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MCG.0000000000000696","article-title":"Biological therapy in pediatric inflammatory bowel disease: A systematic review","volume":"51","author":"Corica","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lawson, M.M., Thomas, A.G., and Akobeng, A.K. (2006). Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev., CD005112.","DOI":"10.1002\/14651858.CD005112.pub2"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Church, P.C., Ho, S., Sharma, A., Tomalty, D., Frost, K., Muise, A., Walters, T.D., and Griffiths, A.M. (2019). Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis. J. Crohns Colitis.","DOI":"10.1093\/ecco-jcc\/jjz019"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MPG.0000000000002036","article-title":"Management of paediatric ulcerative colitis, part 2: Acute severe colitis-an evidence-based consensus guideline from the european crohn\u2019s and colitis organization and the european society of paediatric gastroenterology, hepatology and nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/gut.2007.136481","article-title":"Severe paediatric ulcerative colitis: Incidence, outcomes and optimal timing for second-line therapy","volume":"57","author":"Turner","year":"2008","journal-title":"Gut"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1053\/j.gastro.2010.02.047","article-title":"Severe pediatric ulcerative colitis: A prospective multicenter study of outcomes and predictors of response","volume":"138","author":"Turner","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/MPG.0000000000001024","article-title":"Use of placebo in pediatric inflammatory bowel diseases: A position paper from espghan, ecco, pibdnet, and the canadian children ibd network","volume":"62","author":"Turner","year":"2016","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/ibd.20788","article-title":"Efficacy of infliximab in pediatric crohn\u2019s disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy","volume":"15","author":"Ruemmele","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","article-title":"Safety and efficacy of adalimumab for moderate to severe crohn\u2019s disease in children","volume":"143","author":"Hyams","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.gastro.2013.10.027","article-title":"Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with crohn\u2019s disease","volume":"146","author":"Walters","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(17)30317-3","article-title":"Prediction of complicated disease course for children newly diagnosed with crohn\u2019s disease: A multicentre inception cohort study","volume":"389","author":"Kugathasan","year":"2017","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ecco-jcc\/jjw086","article-title":"Mucosal healing in paediatric patients with moderate-to-severe luminal crohn\u2032s disease under combined immunosuppression: Escalation versus early treatment","volume":"10","author":"Kang","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/MPG.0000000000000711","article-title":"Infliximab \"top-down\" strategy is superior to \"step-up\" in maintaining long-term remission in the treatment of pediatric crohn disease","volume":"60","author":"Lee","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of ct-p13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to ct-p13 and continuing ct-p13 in the planetra extension study","volume":"76","author":"Yoo","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of ct-p13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group planetas study","volume":"18","author":"Park","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.13990","article-title":"Systematic review with meta-analysis: The efficacy and safety of ct-p13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases","volume":"45","author":"Komaki","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/MPG.0000000000002011","article-title":"Use of infliximab biosimilar versus originator in a pediatric united kingdom inflammatory bowel disease induction cohort","volume":"67","author":"Chanchlani","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MPG.0000000000001643","article-title":"Induction therapy with biosimilar infliximab in children with crohn disease","volume":"65","author":"Meglicka","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/archdischild-2017-313404","article-title":"Biosimilar infliximab use in paediatric ibd","volume":"103","author":"Richmond","year":"2018","journal-title":"Arch. Dis. Child."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/ibd\/izx047","article-title":"Long-term outcomes after switching to ct-p13 in pediatric-onset inflammatory bowel disease: A single-center prospective observational study","volume":"24","author":"Kang","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_42","first-page":"144","article-title":"Use of biosimilars in paediatric inflammatory bowel disease: An updated position statement of the paediatric ibd porto group of espghan","volume":"68","author":"Assa","year":"2018","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ibd.20054","article-title":"Predictors of early response to infliximab in patients with ulcerative colitis","volume":"13","author":"Ferrante","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/j.1572-0241.2002.05991.x","article-title":"Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in crohn\u2019s disease","volume":"97","author":"Vermeire","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: Deep remission in biologic and immunomodulator naive patients with crohn\u2019s disease - a sonic post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/MIB.0000000000000225","article-title":"Factors associated with durable response to infliximab in crohn\u2019s disease 5 years and beyond: A multicenter international cohort","volume":"21","author":"Juillerat","year":"2015","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1080\/gas.37.7.818.824","article-title":"A positive response to infliximab in crohn disease: Association with a higher systemic inflammation before treatment but not with -308 tnf gene polymorphism","volume":"37","author":"Louis","year":"2002","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2036.2011.04987.x","article-title":"C-reactive protein, an indicator for maintained response or remission to infliximab in patients with crohn\u2019s disease: A post-hoc analysis from accent i","volume":"35","author":"Reinisch","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1111\/jgh.12324","article-title":"Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A korean multicenter retrospective study","volume":"28","author":"Lee","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","article-title":"Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease","volume":"19","author":"Harper","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/ajg.2010.345","article-title":"A multicenter experience with infliximab for ulcerative colitis: Outcomes and predictors of response, optimization, colectomy, and hospitalization","volume":"105","author":"Oussalah","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: A predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cgh.2013.08.026","article-title":"Phenotypic features of crohn\u2019s disease associated with failure of medical treatment","volume":"12","author":"Moran","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with crohn\u2019s disease: The charm trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-tnf treatment failure in anti-tnf-naive patients with active luminal crohn\u2019s disease: A prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/tpj.2014.19","article-title":"Associations between functional polymorphisms in the nfkappab signaling pathway and response to anti-tnf treatment in danish patients with inflammatory bowel disease","volume":"14","author":"Bank","year":"2014","journal-title":"Pharmacogenomics J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/tpj.2016.84","article-title":"Genetically determined high activity of il-12 and il-18 in ulcerative colitis and tlr5 in crohns disease were associated with non-response to anti-tnf therapy","volume":"18","author":"Bank","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/apt.15187","article-title":"Polymorphisms in the nfkb, tnf-alpha, il-1beta, and il-18 pathways are associated with response to anti-tnf therapy in danish patients with inflammatory bowel disease","volume":"49","author":"Bank","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nm.4307","article-title":"Oncostatin m drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: Predicting and optimising response to anti-tnf therapy in crohn\u2019s disease - algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.cgh.2015.04.010","article-title":"Concomitant use of immunomodulators affects the durability of infliximab therapy in children with crohn\u2019s disease","volume":"13","author":"Grossi","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2036.2010.04507.x","article-title":"The duration of effect of infliximab maintenance treatment in paediatric crohn\u2019s disease is limited","volume":"33","author":"Hummel","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPG.0000000000001551","article-title":"Less anti-infliximab antibody formation in paediatric crohn patients on concomitant immunomodulators","volume":"65","author":"Kansen","year":"2017","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ibd\/izy010","article-title":"The impact of combination therapy on infliximab levels and antibodies in children and young adults with inflammatory bowel disease","volume":"24","author":"Chi","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0000000000000684","article-title":"Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe crohn disease","volume":"60","author":"Kierkus","year":"2015","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ecco-jcc\/jjv126","article-title":"Prospective evaluation of the achievement of mucosal healing with anti-tnf-alpha therapy in a paediatric crohn\u2019s disease cohort","volume":"10","author":"Nuti","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","article-title":"Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with crohn\u2019s disease","volume":"13","author":"Drobne","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15179","article-title":"Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease","volume":"49","author":"Drobne","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/ibd\/izx104","article-title":"Malignancy and mortality in pediatric-onset inflammatory bowel disease: A systematic review","volume":"24","author":"Aardoom","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"j3951","DOI":"10.1136\/bmj.j3951","article-title":"Childhood onset inflammatory bowel disease and risk of cancer: A swedish nationwide cohort study 1964-2014","volume":"358","author":"Olen","year":"2017","journal-title":"B.M.J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/apt.14893","article-title":"Malignancy and mortality in paediatric-onset inflammatory bowel disease: A 3-year prospective, multinational study from the paediatric ibd porto group of espghan","volume":"48","author":"Joosse","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic t-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1053\/j.gastro.2018.10.028","article-title":"Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population","volume":"156","author":"Olen","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: A systematic review","volume":"12","author":"Dulai","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ecco-jcc\/jjw041","article-title":"Higher adalimumab drug levels are associated with mucosal healing in patients with crohn\u2019s disease","volume":"10","author":"Papamichael","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-tnf-alpha therapy: Serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1097\/MIB.0000000000000420","article-title":"The role of therapeutic drug monitoring of anti-tumor necrosis factor alpha agents in children and adolescents with inflammatory bowel disease","volume":"21","author":"Joosse","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11894-018-0623-z","article-title":"Therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"20","author":"Carman","year":"2018","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/gutjnl-2014-308099","article-title":"The association of tissue anti-tnf drug levels with serological and endoscopic disease activity in inflammatory bowel disease: The atlas study","volume":"65","author":"Yarur","year":"2016","journal-title":"Gut"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/apt.13631","article-title":"Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis","volume":"43","author":"Ungar","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Ferrante","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal crohn\u2019s disease","volume":"154","author":"Vermeire","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","article-title":"Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease","volume":"12","author":"Papamichael","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"van Hoeve, K., Dreesen, E., Hoffman, I., Van Assche, G., Ferrante, M., Gils, A., and Vermeire, S. (2019). Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.","DOI":"10.1097\/MPG.0000000000002265"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-tnf discontinuation in inflammatory bowel disease: Systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jpge.2015.11.004","article-title":"Anti-tnf withdrawal in inflammatory bowel disease","volume":"23","author":"Torres","year":"2016","journal-title":"G.E. Port. J. Gastroenterol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/ecco-jcc\/jjx082","article-title":"Vedolizumab in paediatric inflammatory bowel disease: A retrospective multi-centre experience from the paediatric ibd porto group of espghan","volume":"11","author":"Ledder","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for crohn\u2032s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: First- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with crohn\u2019s disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.crohns.2014.06.005","article-title":"Subcutaneous ustekinumab for the treatment of anti-tnf resistant crohn\u2019s disease--the mcgill experience","volume":"8","author":"Kopylov","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Chavannes, M., Martinez-Vinson, C., Hart, L., Kaniki, N., Chao, C.Y., Lawrence, S., Jacobson, K., Hugot, J.P., Viala, J., and Deslandres, C. (2018). Management of paediatric patients with medically-refractory crohn\u2019s disease using ustekinumab: A multi-centred cohort study. J. Crohns Colitis.","DOI":"10.1093\/ecco-jcc\/jjy206"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:54:25Z","timestamp":1760187265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,23]]},"references-count":106,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijms20102529"],"URL":"https:\/\/doi.org\/10.3390\/ijms20102529","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,23]]}}}